Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

$358 $(37)

Net income (loss) per common share -

basic $0.24 $(0.02)

Net income (loss) per common share -

assuming dilution $0.24 $(0.02)

Weighted average shares outstanding -

basic 1,497.5 1,485.5

Weighted average shares outstanding -

assuming dilution 1,504.4 1,485.5

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Nine Months Ended Nine Months Ended

September 30, 2008 September 30, 2007

Impact per Net Impact per

Net diluted (loss) diluted

In millions, except per share data income share income share

GAAP results $358 $0.24 $(37) $(0.02)

Non-GAAP adjustments:

Acquisition-related (credits)

charges (164) (0.11) 104 0.07*

Restructuring-related charges 72 0.05

Litigation-related charges 266 0.18

Divestiture-related (gains) losses (78) (0.06) 352 0.23*

Intangible asset impairment charges 129 0.09

Amortization expense 314 0.21 383 0.25*

Adjusted results $897 $0.60 $802 $0.53

* Assumes dilution of 14.5 million shares for the nine months ended

September 30, 2007 for all or a portion of these non-GAAP adjustments.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document. '/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... - Elsevier, a world-leading provider of scientific, technical and ... of a recent study in Reproductive BioMedicine ... that those with an abnormal chromosomal composition can be ... to blastocysts, thereby classifying the risk of genetic abnormality ... group has undertaken a retrospective study, using their predictive ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... , TORONTO , Jan. 28 ... company developing innovative immune-based biologics, today announced that Dr. ... Directors as an independent director. Trillium Chairman Dr. ... to welcome such an experienced biotech executive as Dr. ...
... ... DNA (or RNA). To help illustrate the basics of DNA origami, Harvard’s Wyss Institute has ... simple, abstract representation of a DNA molecule and then allowing it to self assemble. ... Boston, Mass. (PRWEB) January 28, ...
... , PRINCETON, N.J. , Jan. 27 Covance Inc. ... ended December 31, 2009 of $0.64 per diluted ... a GAAP basis, inclusive of $0.10 per share in gains ... tax resolutions in the third quarter.  Excluding the gains on sales and ...
Cached Biology Technology:Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 2Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 3Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:5/17/2013)... interaction of a group of proteins in the brain ... a new target that could increase cell survival. , ... of Biochemistry and published in the EMBO journal ... lead to new therapies for stroke and other brain ... the team which identified a protein, known as SUMO, ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... Reportlinker.com announces that a new ... Biometrics: Technologies and Global Markets ... AND OBJECTIVESThis report studies the global as well as ... purpose of locating newer markets and expanding the present ...
... project using cameras mounted on unmanned aircraft flying over the ... declining sea ice and using the same aerial photos to ... The project is the first to use aircraft to monitor ... observers at risk, said Elizabeth Weatherhead of the University of ...
... reactions that asthmatics suffer towards a common mould have ... mould growing in their own lungs. The research ... has been published in the December 2010 issue of ... Medicine . The team based in the Institute ...
Cached Biology News:Reportlinker Adds Biometrics: Technologies and Global Markets 2Reportlinker Adds Biometrics: Technologies and Global Markets 3Reportlinker Adds Biometrics: Technologies and Global Markets 4Reportlinker Adds Biometrics: Technologies and Global Markets 5Reportlinker Adds Biometrics: Technologies and Global Markets 6Reportlinker Adds Biometrics: Technologies and Global Markets 7Reportlinker Adds Biometrics: Technologies and Global Markets 8Reportlinker Adds Biometrics: Technologies and Global Markets 9Reportlinker Adds Biometrics: Technologies and Global Markets 10Reportlinker Adds Biometrics: Technologies and Global Markets 11Reportlinker Adds Biometrics: Technologies and Global Markets 12Reportlinker Adds Biometrics: Technologies and Global Markets 13Reportlinker Adds Biometrics: Technologies and Global Markets 14Reportlinker Adds Biometrics: Technologies and Global Markets 15Reportlinker Adds Biometrics: Technologies and Global Markets 16Reportlinker Adds Biometrics: Technologies and Global Markets 17Reportlinker Adds Biometrics: Technologies and Global Markets 18Reportlinker Adds Biometrics: Technologies and Global Markets 19Reportlinker Adds Biometrics: Technologies and Global Markets 20Reportlinker Adds Biometrics: Technologies and Global Markets 21Reportlinker Adds Biometrics: Technologies and Global Markets 22High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 2High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 3New asthma research breaks the mold 2
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Medium for cryopreserving subcutaneous or omental preadipocytes...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Biology Products: